Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

390 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Phase II/III study comparing carboplatin and irinotecan with carboplatin and etoposide for the treatment of elderly patients with extensive-disease small-cell lung cancer (JCOG1201).
Eba J, Shimokawa T, Nakamura K, Shibata T, Misumi Y, Okamoto H, Yamamoto N, Ohe Y; Lung Cancer Study Group of the Japan Clinical Oncology Group. Eba J, et al. Among authors: misumi y. Jpn J Clin Oncol. 2015 Jan;45(1):115-8. doi: 10.1093/jjco/hyu166. Epub 2014 Oct 20. Jpn J Clin Oncol. 2015. PMID: 25332420 Clinical Trial.
Phase I/II study of induction chemotherapy using carboplatin plus irinotecan and sequential thoracic radiotherapy (TRT) for elderly patients with limited-disease small-cell lung cancer (LD-SCLC): TORG 0604.
Misumi Y, Okamoto H, Sasaki J, Masuda N, Ishii M, Shimokawa T, Hosomi Y, Okuma Y, Nagamata M, Ogura T, Kato T, Sata M, Otani S, Takakura A, Minato K, Miura Y, Yokoyama T, Takata S, Naoki K, Watanabe K. Misumi Y, et al. BMC Cancer. 2017 May 26;17(1):377. doi: 10.1186/s12885-017-3353-y. BMC Cancer. 2017. PMID: 28549414 Free PMC article. Clinical Trial.
Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016.
Ikeda S, Kato T, Ogura T, Sekine A, Oda T, Masuda N, Igawa S, Katono K, Otani S, Yamada K, Saito H, Kondo T, Hosomi Y, Nakahara Y, Nishikawa M, Utumi K, Misumi Y, Yamanaka T, Sakamaki K, Okamoto H. Ikeda S, et al. Among authors: misumi y. BMC Cancer. 2018 Mar 2;18(1):241. doi: 10.1186/s12885-018-4150-y. BMC Cancer. 2018. PMID: 29499653 Free PMC article. Clinical Trial.
Comparison of the efficacies of first-generation epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in patients with advanced non-small-cell lung cancer harboring EGFR mutations.
Aiko N, Shimokawa T, Miyazaki K, Misumi Y, Agemi Y, Ishii M, Nakamura Y, Yamanaka T, Okamoto H. Aiko N, et al. Among authors: misumi y. BMC Cancer. 2018 Oct 22;18(1):1012. doi: 10.1186/s12885-018-4911-7. BMC Cancer. 2018. PMID: 30348116 Free PMC article.
Efficacy of PD-1 Inhibitors in Older Non-small Cell Lung Cancer Patients.
Nakamura Y, Miyazaki K, Aiko N, Misumi Y, Agemi Y, Taniguchi Y, Ishi M, Shimokawa T, Okamoto H, Yamanaka T. Nakamura Y, et al. Among authors: misumi y. Anticancer Res. 2020 Feb;40(2):923-928. doi: 10.21873/anticanres.14025. Anticancer Res. 2020. PMID: 32014936
Phase I/II study of erlotinib plus S-1 for patients with previously treated non-small cell lung cancer: Thoracic Oncology Research Group (TORG) 0808/0913.
Nakahara Y, Shimokawa T, Misumi Y, Nogami N, Shinkai T, Seki N, Hosomi Y, Hida N, Okamoto H. Nakahara Y, et al. Among authors: misumi y. Invest New Drugs. 2021 Feb;39(1):202-209. doi: 10.1007/s10637-020-00985-4. Epub 2020 Aug 15. Invest New Drugs. 2021. PMID: 32803700 Free PMC article. Clinical Trial.
390 results